Effects of ivabradine on vascular function in individuals at increased risk of developing cardiovascular disease and with impaired endothelial function An international, multicentre, randomised, double-blind, placebo-controlled study over 12 weeks.
Phase of Trial: Phase II
Latest Information Update: 06 Feb 2019
Price : $35 *
At a glance
- Drugs Ivabradine (Primary)
- Indications Cardiovascular disorders
- Focus Biomarker; Pharmacodynamics
- Sponsors Servier
- 06 Feb 2019 This trial has been Discontinued in UK - MHRA, according to European Clinical Trials Database.
- 02 Feb 2019 Germany, France and Switzerland were planned locations according to European Clinical Trials Database.
- 02 Feb 2019 Status changed from recruiting to discontinued.